NextGen divests automation and software business
This article was originally published in Scrip
NextGen Sciences, a US-based biomarker service provider, has sold its gene-to-protein automation and software business to eXeTek, a management-led spin-out from the company. The divestment is past of NextGen's plan announced in April to focus all resources on growing its protein biomarker services business. NextGen has acquired a 24% stake in eXeTek, which will be led by former employees Stephen Woodall and Stuart Hill, and will receive 5% royalties on sales for three years. NextGen's protein service portfolio, which it calls biomarker express, includes biomarker discovery and assay development and testing.